Cefazolin, injection, 1 gram per vial, 25 vials per box, sterile, Rx only, single-use vial, Manuf...
FDA Drug Recall #D-597-2013 — Class II — May 30, 2013
Recall Summary
| Recall Number | D-597-2013 |
| Classification | Class II — Moderate risk |
| Date Initiated | May 30, 2013 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Sandoz Incorporated |
| Location | Broomfield, CO |
| Product Type | Drugs |
| Quantity | 297,200 vials |
Product Description
Cefazolin, injection, 1 gram per vial, 25 vials per box, sterile, Rx only, single-use vial, Manufactured in Austria by Sandoz GmbH for Sandoz, Inc. Princeton, NJ 08540, NDC 00781-3451-70 (vial), NDC 00781-3451-96 (box)
Reason for Recall
Lack of Assurance of Sterility: Sandoz Inc is recalling Cefazolin for Injection, USP 1 gm vials, lot DB2208, due to a customer complaint for broken/cracked vials which was confirmed through review of retained samples.
Distribution Pattern
Nationwide and Puerto Rico.
Lot / Code Information
Lot #: DB2208, Exp 01/16
Other Recalls from Sandoz Incorporated
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0631-2018 | Class III | Triamterene and Hydrochlorothiazide Tablets, US... | Apr 6, 2018 |
| D-0943-2017 | Class III | Amitriptyline HCl Tablets, USP 25 mg, Packaged ... | Jun 16, 2017 |
| D-0236-2017 | Class II | Nadolol Tablets, USP, 40mg, packaged in 1000-co... | Dec 22, 2016 |
| D-0291-2015 | Class III | Fluoxetine Capsules USP, 20 mg, 100 count bottl... | Dec 5, 2014 |
| D-1509-2014 | Class II | Alprazolam Tablets, USP, 0.25mg, Rx only, 1000 ... | Jul 25, 2014 |
Frequently Asked Questions
Injectable drugs and eye drops must be completely free of microbial contamination because they bypass the body's natural defenses. A contaminated injectable can introduce bacteria or fungi directly into the bloodstream, potentially causing sepsis, meningitis, or localized infections — all of which can be life-threatening. Contamination of sterile products almost always results in a Class I recall. If you received an injectable drug from a recalled lot, contact your healthcare provider immediately, even if you feel well, as some infections can have delayed onset.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.